近年，胰腺癌相关糖尿病研究进展为早期胰腺癌筛查提供了突破口。本课题组09年在国际上率先研究新发糖尿病相关胰腺癌（PCAD）外周血特异标记物，发现了PCAD系列特异基因，研究结果2010年在AJG发表。该研究结果证明：通过靶标筛查和分子影像学技术在新发糖尿病人群中筛查早期胰腺癌患者的创新设想具备实际可行性。结合我们近期取得靶向示踪胰岛的研究进展，本项目首次设想：利用PCAD动物模型，在病程关键点筛查外周血及肿瘤原位的特异性标记物；其次，构建荧光/磁共振双重显像的靶向探针（CNT-SPIO-QDs-X），并验证其时效量效扫描参数；最后研究双重示踪靶向探针在监测仓鼠PCAD模型病程发展过程中的作用及价值。整个研究策略和流程旨在建立完善的动物体内早期胰腺癌预警系统， 以推动临床早期胰腺癌诊疗治疗出现重大进展。

In recent years,the research and progression of pancreatic cancer associated diabetes（PCAD） provides prospect for early-phase pancreatic cancer screening.Our group took the lead in studying peripheral blood specific marker of de novo PCAD in 2009 and found PCAD specific gene,which result was published in AJG in 2010.Our research demonstrates that it is practically feasible of early-phase pancreatic cancer screening in PCAD patients by way of serun marker screening and molecular imaging technology.Combining the progression of targeted-tracing pancreatic islet recently,we take the lead in envisaging that peripheral blood and tumor orthotopic specific markers are screened in key points of disease-process through PCAD animal model.Then fluorescence/MRI dual imaging targeted probes are constructed（CNT-SPIO-QDs-X） and their time effect、graded effect screening parameters are tested and verified.Finally,the application of the dual tracing targeted probes in monitoring animal PCAD disease-process is studied.The aim of whole study strategy and technological process is to establish and consummate early-phase pancreatic cancer prewarning system in vivo in animal model,thereby to make great progression of clinical early-phase pancreatic cancer diagnosis and treatment.